Imatinib, a tyrosine kinase inhibitor that blocks the catalytic activity of BCR/ABL, has demonstrated unprecedented efficacy for treatment of CML or Ph+ ALL (12–14). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.